Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282627 | Clinical Gastroenterology and Hepatology | 2013 | 12 Pages |
Abstract
For patients with short-bowel syndrome intestinal failure, the efficacy of teduglutide was maintained over 52 weeks and the safety profile was sufficient for it to be considered for long-term use. Further studies are needed to determine whether these effects will translate into improved quality of life and reduced PN complications. ClinicalTrials.gov number, NCT00172185.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Stephen J.D. O'Keefe, Palle B. Jeppesen, Richard Gilroy, Marek Pertkiewicz, Johane P. Allard, Bernard Messing,